Travel grant, Swiss Nordic Bio 2020,6 February in Zürich
| Reference number | |
| Coordinator | CombiGene AB |
| Funding from Vinnova | SEK 15 000 |
| Project duration | January 2020 - February 2020 |
| Status | Completed |
Important results from the project
The purpose of participating in Swiss Nordic Bio 2020 was to present the company to potential partners in Big Pharma and investors, respectively. We reached the target in terms of investors, but Big Pharma was not represented even though this was the organizers´ expectation.
Expected long term effects
We met with several investors that we have had no contact with before and we have followed up with sending a company presentation. We will follow up with contact via mail / phone. The goal is to get a direct investment in the company.
Approach and implementation
We attended the Swiss Nordic Bio conference and presented the company partly in a public presentation for about 100 participants and we conducted individual meetings with selected participants. We met several investors that we had not had contact with before, which was very valuable. However, Big Pharma was not represented even though this was the organizers´ expectation.